Narlaprevir (BioDeep_00000760392)
代谢物信息卡片
化学式: C36H61N5O7S (707.4291476000001)
中文名称: 那拉匹韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3C(C3(C)C)CN2C(=O)C(C(C)(C)C)NC(=O)NC4(CCCCC4)CS(=O)(=O)C(C)(C)C
InChI: InChI=1S/C36H61N5O7S/c1-10-11-15-24(27(42)30(44)37-22-16-17-22)38-29(43)26-25-23(35(25,8)9)20-41(26)31(45)28(33(2,3)4)39-32(46)40-36(18-13-12-14-19-36)21-49(47,48)34(5,6)7/h22-26,28H,10-21H2,1-9H3,(H,37,44)(H,38,43)(H2,39,40,46)/t23-,24-,25-,26-,28+/m0/s1
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:173104
- KEGGdrug: D09644
- PubChem: 11857239
- ChEMBL: CHEMBL1255891
- CAS: 865466-24-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Daniel W Kneller, Hui Li, Gwyndalyn Phillips, Kevin L Weiss, Qiu Zhang, Mark A Arnould, Colleen B Jonsson, Surekha Surendranathan, Jyothi Parvathareddy, Matthew P Blakeley, Leighton Coates, John M Louis, Peter V Bonnesen, Andrey Kovalevsky. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Nature communications.
2022 04; 13(1):2268. doi:
10.1038/s41467-022-29915-z. [PMID: 35477935] - Anjela Manandhar, Benjamin E Blass, Dennis J Colussi, Imane Almi, Magid Abou-Gharbia, Michael L Klein, Khaled M Elokely. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening.
Journal of chemical information and modeling.
2021 02; 61(2):1020-1032. doi:
10.1021/acs.jcim.0c01457. [PMID: 33538596] - Yu Bai, Fei Ye, Yong Feng, Hanyi Liao, Hao Song, Jianxun Qi, George Fu Gao, Wenjie Tan, Lifeng Fu, Yi Shi. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.
Signal transduction and targeted therapy.
2021 02; 6(1):51. doi:
10.1038/s41392-021-00468-9. [PMID: 33542181] - V Isakov, D Koloda, N Tikhonova, T Kikalishvili, E Krasavina, K Lekishvili, I Malaya, M Ryska, M Samsonov, V Tolkacheva. Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.
Antimicrobial agents and chemotherapy.
2016 12; 60(12):7098-7104. doi:
10.1128/aac.01044-16. [PMID: 27645244] - Lan Gao, Jing Li, Claudia Kasserra, Qi Song, Ali Arjomand, David Hesk, Swapan K Chowdhury. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
Analytical chemistry.
2011 Jul; 83(14):5607-16. doi:
10.1021/ac2006284. [PMID: 21627104] - Jennifer M Cunliffe, Jim X Shen, Xianrong Wei, Daniel P Dreyer, Roger N Hayes, Robert P Clement. Implementation of high-temperature superficially porous technologies for rapid LC-MS/MS diastereomer bioanalysis.
Bioanalysis.
2011 Apr; 3(7):735-43. doi:
10.4155/bio.11.17. [PMID: 21452991] - Jennifer M Cunliffe, Daniel P Dreyer, Roger N Hayes, Robert P Clement, Jim X Shen. Using temperature to optimize resolution and reduce analysis times for bioanalytical diastereomer LC-MS/MS separations.
Journal of pharmaceutical and biomedical analysis.
2011 Jan; 54(1):179-85. doi:
10.1016/j.jpba.2010.08.017. [PMID: 20837385] - Joep de Bruijne, Jilling F Bergmann, Henk W Reesink, Christine J Weegink, Richard Molenkamp, Janke Schinkel, Xiao Tong, Jing Li, Michelle A Treitel, Eric A Hughes, Jan Jaap van Lier, Andre A van Vliet, Harry L A Janssen, Robert J de Knegt. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Hepatology (Baltimore, Md.).
2010 Nov; 52(5):1590-9. doi:
10.1002/hep.23899. [PMID: 20938912]